We analyzed prognostic factors in 148 patients with SNADETs, focusing on TNM stage, the anatomical location of the tumor, KRAS mutation, BRAF mutation, Fn, mucin phenotype, and PD-L1 status. This evidence concerns the gene BRAF and neoplasm.